3728 Jinke Rd, Building 1, West Wing, Shanghai, China
info@tyligand.com
Chinese Version（中文版）
current-item active">
Home
About
Company Profile
Leadership Team
Investors
Research
Focusing Fields
Platforms
Pipelines
Partnership
News
Corporate News
Career
Talent Philosophies
Join Tyligand
Contact
2024
Enter Part of Title
Filter
Clear
Display #
5
10
15
20
25
30
50
100
All
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting
